去甲基化药物治疗骨髓增生异常综合征:治疗失败原因及其解决方案

焦蒙; 肖志坚

doi:10.13201/j.issn.1004-2806.2019.03.018

去甲基化药物治疗骨髓增生异常综合征:治疗失败原因及其解决方案

焦蒙,
肖志坚^,

- 中国医学科学院血液病医院(血液学研究所)(天津, 300020)

详细信息

通讯作者: 肖志坚,E-mail:zjxiao@hotmail.com

中图分类号: R733

收稿日期: 2018-07-24

Failure of hypomethylating agents in the treatment of myelodysplastic syndrome:causes and therapeutic choices

JIAO Meng,
XIAO Zhijian^,

More Information

Corresponding author: XIAO Zhijian, E-mail: zjxiao@hotmail.com

Received Date: 24 July 2018

摘要

- 骨髓增生异常综合征 /
- 地西他滨 /
- 阿扎胞苷 /
- 治疗失败
Abstract: The hypomethylating agents (HMA) azacitidine and decitabine are the standard treatment of patients with myelodysplastic syndromes.However,most patients experience treatment failure including HMA intolerance,no response or response lost.Therefore,it is important to understand patterns of failure to select appropriate salvage treatment.Supportive care should be given in the circumstances of serious adverse effects.If the patient shows no response or relapses after initial response,the alternative treatment options include allogeneic hematopoietic stem cell transplantation,targeted agents,chemotherapy,histone deacetylase inhibitors and immunomodulators.
- myelodysplastic syndrome /
- decitabine /
- azacitidine /
- treatment failure

HTML全文

参考文献(38)

[1]	肖志坚.骨髓增生异常综合征的精准诊断与治疗:现况与问题[J].临床血液学杂志,2017,30(5):339-341.
[2]	Steensma DP,Baer MR,Slack JL,et al.Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes:the alternative dosing for outpatient treatment (ADOPT) trial[J].J Clin Oncol,2009,27:3842-3848.
[3]	Kantarjian H,Oki Y,Garcia-Manero G,et al.Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia[J].Blood,2007,109:52-57.
[4]	Silverman LR,Fenaux P,Mufti GJ,et al.Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes[J].Cancer,2011,117:2697-2702.
[5]	Cabrero M,Jabbour E,Ravandi F,et al.Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response:retrospective analysis of survival after long-term follow-up[J].Leuk Res,2015,39:520-524.
[6]	Prebet T,Gore SD,Esterni B,et al.Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure[J].J Clin Oncol,2011,29:3322-3327.
[7]	Fenaux P,Mufti GJ,Hellstrom-Lindberg E,et al.Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes:a randomised,open-label,phase III study[J].Lancet Oncol,2009,10:223-232.
[8]	Santini V,Fenaux P,Mufti GJ,et al.Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine[J].Eur J Haematol,2010,85:130-138.
[9]	Wu D,Du X,Jin J,et al.Decitabine for treatment of myelodysplastic syndromes in chinese patients:an open-label,phase-3b study[J].Adv Ther,2015,32:1140-1159.
[10]	Lee JH,Jang JH,Park J,et al.A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome[J].Haematologica,2011,96:1441-1447.
[11]	Itzykson R,Thepot S,Beyne-Rauzy O,et al.Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?[J].Leuk Res,2012,36:397-400.
[12]	Greenberg PL,Garcia-Manero G,Moore M,et al.A randomized controlled trial of romiplostim in patients with low-or intermediate-risk myelodysplastic syndrome receiving decitabine[J].Leuk Lymphoma,2013,54:321-328.
[13]	Jabbour E,Garcia-Manero G,Cornelison AM,et al.The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes[J].Leuk Lymphoma,2015,56:390-394.
[14]	Fenaux P,Bowen D,Gattermann N,et al.Practical use of azacitidine in higher-risk myelodysplastic syndromes:an expert panel opinion[J].Leuk Res,2010,34:1410-1416.
[15]	Trubiano JA,Dickinson M,Thursky KA,et al.Incidence,etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes[J].Leuk Lymphoma,2017,58:2379-2386.
[16]	Merkel D,Filanovsky K,Gafter-Gvili A,et al.Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine:a retrospective multicenter study[J].Am J Hematol,2013,88:130-134.
[17]	Radsak M,Platzbecker U,Schmidt CS,et al.Infectious complications in patients with myelodysplastic syndromes:A review of the literature with emphasis on patients treated with 5-azacitidine[J].Eur J Haematol,2017,99:112-118.
[18]	Komrokji RS.Treatment of higher-risk myelodysplastic syndromes after failure of hypomethylating agents[J].Clin Lymphoma Myeloma Leuk,2015,15 Suppl:S56-S59.
[19]	Unnikrishnan A,Papaemmanuil E,Beck D,et al.Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes[J].Cell Rep,2017,20:572-585.
[20]	Shin SH,Yahng SA,Yoon JH,et al.Survival benefits with transplantation in secondary AML evolving from myelodysplastic syndrome with hypomethylating treatment failure[J].Bone Marrow Transplant,2013,48:678-683.
[21]	Della Porta MG,Alessandrino EP,Bacigalupo A,et al.Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R[J].Blood,2014,123:2333-2342.
[22]	Shaffer BC,Ahn KW,Hu ZH,et al.Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome[J].J Clin Oncol,2016,34:1864-1871.
[23]	Festuccia M,Baker K,Gooley TA,et al.Hematopoietic cell transplantation in myelodysplastic syndromes after treatment with hypomethylating agents[J].Biol Blood Marrow Transplant,2017,23:1509-1514.
[24]	Kroger N.Maximizing the benefit of allogeneic stem cell transplantation in myelodysplastic syndromes[J].Semin Hematol,2017,54:154-158.
[25]	Garcia-Manero G,Fenaux P,Al-Kali A,et al.Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME):a randomised,controlled,phase 3 trial[J].Lancet Oncol,2016,17:496-508.
[26]	Stein EM,DiNardo CD,Pollyea DA,et al.Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia[J].Blood,2017,130:722-731.
[27]	Stone RM,Mandrekar SJ,Sanford BL,et al.Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation[J].N Engl J Med,2017,377:454-464.
[28]	Strati P,Kantarjian H,Ravandi F,et al.Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome[J].Am J Hematol,2015,90:276-281.
[29]	Zeidan AM,Kharfan-Dabaja MA,Komrokji RS.Beyond hypomethylating agents failure in patients with myelodysplastic syndromes[J].Curr Opin Hematol,2014,21:123-130.
[30]	Jabbour E,Faderl S,Sasaki K,et al.Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents[J].Cancer,2017,123:629-637.
[31]	Prebet T,Sun Z,Figueroa ME,et al.Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes:results of the US Leukemia Intergroup trial E1905[J].J Clin Oncol,2014,32:1242-1248.
[32]	Jaglal MV,Duong VH,Bello CM,et al.Cladribine,cytarabine,filgrastim,and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure[J].Leuk Res,2014,38:443-446.
[33]	Prebet T,Charbonnier A,Gelsi-Boyer V,et al.Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure[J].Leuk Lymphoma,2013,54:1538-1540.
[34]	Cherian MA,Tibes R,Gao F,et al.A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome[J].Leuk Lymphoma,2016,57:2535-2540.
[35]	Apuri S,Al Ali N,Padron E,et al.Evidence for selective benefit of sequential treatment with hypomethylating agents in patients with myelodysplastic syndrome[J].Clin Lymphoma Myeloma Leuk,2017,17:211-214.
[36]	Qin T,Castoro R,El Ahdab S,et al.Mechanisms of resistance to decitabine in the myelodysplastic syndrome[J].PLoS One,2011,6:e23372.
[37]	Duong VH,Bhatnagar B,Zandberg DP,et al.Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine[J].Leuk Lymphoma,2015,56:1718-1722.
[38]	Harel S,Cherait A,Berthon C,et al.Outcome of patients with high risk myelodysplastic syndrome (MDS) and advanced chronic myelomonocytic leukemia (CMML) treated with decitabine after azacitidine failure[J].Leuk Res,2015,39:501-504.